Harmony Biosciences is trading at $41.00, up +7.02% in after-hours trading versus the regular-session close, amid broader market gains. - The Nasdaq advanced 1.07% and the S&P 500 rose 0.55%. - No verified company-specific announcement on October 21 explains the move. The latest company release scheduled Q3 results for November 4. - The CEO succession announcement was dated October 12 and is prior context, not a confirmed new catalyst.